Telix Pharmaceuticals (ASX:TLX)
Company Profile
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Telix Pharmaceuticals.
RELATED STOCKHEAD STORIES
Closing Bell: ASX rallies as Trump softens up on tariffs; Capricorn CEO faces charge
Lunch Wrap: ASX lights up as risk returns; Paladin rockets 25pc but gold sees heavy profit-taking
Health Check: Telix shares rocket after bullish quarterly sales update
Health Check: Drug sector panic sets in at the prospect of a Trump tariff ‘pharma-geddon’
Health Check: Relax! Tariffs shape as the next Y2K as biotechs report ‘nothing to see here’
Health Check: Liberation Day spares the global drug sector – for now
Biocurious: While other biotechs scratch around for cash, Clinuvel is accused of having too much
Closing Bell: Tech tumble and Trump tariffs trample Thursday
Health Check: ASX ‘Magnificent Seven’ rides high amidst the US healthcare mayhem
Health Check: Opthea’s solvency in question after monumental phase III eye disease trial failure
Biocurious: FDA approval remains the Holy Grail for ASX life science stocks
Health Check: Fantastico! Telix wins Brazilian assent for prostate cancer imaging agent
Health Check: Telix ‘mini me’ Clarity moves to next phase of prostate cancer therapy trial
